Neuromodulation Treatment of Vestibular Migraines
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Neuromodulation Treatment of Vestibular Migraines|
- Dizziness Handicap Inventory [ Time Frame: Until study completion up to 12 months ]Questionnaire of dizziness symptoms
- Headache Impact Test [ Time Frame: Until study completion up to 12 months ]Headache questionnaire
- Activities Balance Confidence Interval [ Time Frame: Until study completion up to 12 months ]Dizziness questionnaire
- OVRT Testing [ Time Frame: Until study completion up to 12 months ]Oculomotor, vestibular, and reaction time tests
- Epworth Sleepiness Scale [ Time Frame: Until study completion up to 12 months ]Sleepiness questionnaire
- T2 Mood Tracker app [ Time Frame: Until study completion up to 12 months ]App to assess mood and anxiety
|Actual Study Start Date:||September 28, 2016|
|Estimated Study Completion Date:||March 2018|
|Estimated Primary Completion Date:||March 2018 (Final data collection date for primary outcome measure)|
The following parameters will be set for active treatments using the CVS Device:
Other Name: Caloric stimulation
This is a non-blinded, non-randomized pilot study of individuals with vestibular migraines. The goal is to test the efficacy of neuromodulation on both migraine and dizziness symptoms in patients with documented vestibular migraines. Treatment will consist of 9 months of active treatment followed by 3 months of observation. The active treatment requires two daily 20 minute sessions wearing a device over the ears that delivers a very small amount of warm air to the ears. All subjects will undergo a series of tests at baseline and at discrete intervals during the 1 year of observation.
Primary and Secondary endpoints are listed below:• Primary Efficacy Endpoints
- Reduction in the frequency and severity of migraine headaches (self reported in pain diary)
- Reduction in the frequency and intensity of perceived vestibular symptoms (Dizziness Handicap Inventory (DHI), Activity Balance confidence scale (ABC), Oscillopsia Test, Symptoms questionnaire), OVRT Goggle profile.
Secondary Efficacy Endpoints for the Pilot Study
- Improvement in sleep quality and/or quantity as assessed by the Epworth Sleep Scale.
- Improvement in quality of life as assessed by the HIT-6 survey.
- Improvement in mood/anxiety as assessed with the T2 Mood Tracker app (National Center for Telehealth & Technology).
Please refer to this study by its ClinicalTrials.gov identifier: NCT02866084
|United States, Florida|
|University of Miami Miller School of Medicine||Recruiting|
|Miami, Florida, United States, 33136|
|Contact: Michael E Hoffer, MD 305-243-3564 firstname.lastname@example.org|